(Q35196317)

7 August 2017

1 reference

title

CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry (English)

1 reference

7 August 2017

0 references

0 references

1

Kaj Blennow

1 reference

7 August 2017

2

Eugeen Vanmechelen

1 reference

7 August 2017

1 August 2003

1 reference

7 August 2017

Brain Research Bulletin

1 reference

7 August 2017

61

1 reference

7 August 2017

3

1 reference

7 August 2017

235-242

1 reference

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Clinical-neuropathological correlations in Alzheimer's disease and related dementias

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Tau protein and the neurofibrillary pathology of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Diagnostic accuracy of Alzheimer's disease: a clinicopathological study.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Increased cerebrospinal fluid tau in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Diagnostic accuracy of Alzheimer's disease: a neuropathological study.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Tau Protein in Cerebrospinal Fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Cerebrospinal protein tau is elevated in early Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Both total and phosphorylated tau are increased in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2803%2900086-8

7 January 2021

10.1016/S0361-9230(03)00086-8

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12909293